Alzheon to Present Results from Trials of ALZ-801 in Early Alzheimer’s at AAIC

Alzheon, Inc., a clinical-stage biopharmaceutical firm, is actively advancing treatments for Alzheimer’s disease (AD) and related neurodegenerative disorders. The company has announced its significant participation in the Alzheimer’s Association International Conference (AAIC) in Philadelphia, scheduled from July 28 to August 1, 2024. The conference will serve as a platform for Alzheon to showcase its latest research and progress in the fight against Alzheimer’s.

Susan Abushakra, MD, Alzheon’s Chief Medical Officer, highlighted the importance of their contributions to the conference, emphasizing the company’s dedication to transforming the landscape of Alzheimer’s treatment. She noted the promising potential of their lead product, ALZ-801 (valiltramiprosate), as an innovative oral therapy that could simplify treatment and improve accessibility for patients. The upcoming topline results from their pivotal APOLLOE4 Phase 3 trial are highly anticipated and could support ALZ-801 as the first oral treatment to decelerate Alzheimer’s disease progression.

Alzheon is set to deliver four presentations at the conference, comprising two oral sessions and two posters. The first oral presentation, titled “Phase 3 Trial of Oral Anti-Amyloid Agent ALZ-801/Valiltramiprosate in APOE4/4 Homozygotes with Early Alzheimer’s Disease: Baseline Characteristics and Prevalence of Comorbid Cerebral Amyloid Angiopathy,” will be presented by Dr. Aidan Power, the company’s Chief Development Officer, on July 31, 2024, from 8:00 a.m. to 8:45 a.m. ET.

The second oral presentation is a Featured Research Symposium titled “Plasma Biomarkers, Hippocampal Volume and Cognitive Effects of Oral ALZ-801: The Phase 2 Biomarker Study and its Long-Term Extension in APOE4 Carriers with Early Alzheimer’s Disease.” Dr. Susan Abushakra will present this session on the same day from 9:00 a.m. to 10:30 a.m. ET.

The first poster presentation, “Use of External Comparator-Arm from ADNI-1 for the ALZ-801/Valiltramiprosate Phase 2 Study of APOE4 Carriers with Early Alzheimer’s Disease: Regulatory Basis and Statistical Considerations,” will be presented by Dr. John Hey, Alzheon’s Chief Scientific Officer, on July 29, 2024, between 7:30 a.m. and 4:15 p.m. ET.

The second poster, titled “Low Incidence of Amyloid Related Imaging Abnormalities over 104 Weeks in a Phase 2 Study of Amyloid Anti-Oligomer Agent ALZ-801 (Valiltramiprosate) in Biomarker Positive APOE4 Carriers with Early Alzheimer’s Disease,” will be presented by Dr. Patrick Kesslak, Senior Clinical Research Fellow, on July 30, 2024, from 7:30 a.m. to 4:15 p.m. ET.

ALZ-801 is a cutting-edge investigational oral agent currently in Phase 3 development, targeting the modification of Alzheimer’s disease progression. It works by blocking the formation of neurotoxic soluble beta amyloid oligomers, which are believed to contribute to cognitive decline in Alzheimer’s patients. The drug has demonstrated robust efficacy and safety profiles in clinical trials, showing no increased risk of brain vasogenic edema.

ALZ-801 received Fast Track designation from the U.S. Food and Drug Administration in 2017, underscoring its potential as a significant advancement in Alzheimer’s treatment. The initial Phase 3 program is focused on patients with early-stage Alzheimer’s who have two copies of the APOE4 allele, with plans for future expansion to broader patient groups.

Alzheon’s dedication to developing innovative treatments is clear in their comprehensive clinical trials and the engagement in significant scientific dialogues at conferences like AAIC. Their approach, which integrates precision medicine based on genetic and biomarker information, aims to deliver the most effective therapies for patients suffering from Alzheimer’s disease and other neurodegenerative disorders.